The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease or GERD. The agency ...
ROCKVILLE, Md. The Food and Drug Administration on Thursday approved prescription Nexium for short-term use in children ages 1-to-11 years for the treatment of gastroesophageal reflux disease in two ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) announced today that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM ® I.V. (esomeprazole sodium) for Injection ...
AstraZeneca announced that the FDA has approved Nexium IV (esomeprazole sodium for injection) for use in children >1 month of age for the short-term treatment of gastroesophageal reflux disease (GERD) ...
The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease. FDA said Thursday it approved liquid and delayed-release capsules of Nexium ...
WILMINGTON, DE, May 12, 2005 – Results from two clinical trials, published in the American Journal of Gastroenterology, demonstrate that NEXIUM® (esomeprazole magnesium) can reduce upper ...
The FDA this week cleared AstraZeneca to market its heartburn treatment Nexium to children ages 12 through 17 for the treatment of gastroesophageal reflux disease. Nexium had global sales of $4.6 ...
This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. The Food and Drug Administration warned today that patients taking the ...
CHICAGO -- U.S. employers, struggling to tame double-digit health inflation, are putting the squeeze on AstraZeneca's ulcer drug Nexium, a product the Anglo-Swedish drug maker sorely needs to boost ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback